Detalhe da pesquisa
1.
An NK-like CAR T cell transition in CAR T cell dysfunction.
Cell
; 184(25): 6081-6100.e26, 2021 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34861191
2.
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells.
Immunity
; 56(10): 2388-2407.e9, 2023 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37776850
3.
Intratumoral Delivery of Immunotherapy-Act Locally, Think Globally.
J Immunol
; 198(1): 31-39, 2017 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27994166
4.
Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
Eur J Immunol
; 46(3): 513-22, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26773716
5.
Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice.
Proc Natl Acad Sci U S A
; 109(26): 10534-9, 2012 Jun 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-22689981
6.
Routing cancer immunology and immunotherapy from the lab to the clinic 4-5 th March 2014, Center for Applied Medical Research and University Clinic, Pamplona, Spain.
J Transl Med
; 12: 202, 2014 Jul 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-25060862
7.
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors.
Sci Transl Med
; 12(565)2020 10 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33055241
8.
Immunotherapeutic effects of intratumoral nanoplexed poly I:C.
J Immunother Cancer
; 7(1): 116, 2019 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31046839
9.
Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells.
Cancer Cell
; 36(6): 613-629.e7, 2019 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31761658
10.
CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes.
Cancer Immunol Res
; 6(1): 69-78, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29133290
11.
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.
Nat Commun
; 9(1): 4809, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30442944
12.
CD69 is a direct HIF-1α target gene in hypoxia as a mechanism enhancing expression on tumor-infiltrating T lymphocytes.
Oncoimmunology
; 6(4): e1283468, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28507790
13.
Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells.
Cancer Discov
; 6(1): 71-9, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26493961
14.
Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.
J Thorac Oncol
; 11(4): 524-36, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26845193
15.
Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism.
Oncoimmunology
; 5(1): e1062967, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26942078
16.
Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.
Cancer Res
; 76(20): 5994-6005, 2016 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27550452
17.
Evolving synergistic combinations of targeted immunotherapies to combat cancer.
Nat Rev Cancer
; 15(8): 457-72, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26205340
18.
Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade.
Cancer Immunol Res
; 3(5): 449-54, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25691326